Galecto begins third phase II trial
The first patient has now received a dose of Galecto's drug candidate GB1211 in a crucial phase 1b/2a trial meant to assess its efficacy in treating liver cirrhosis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
With the first dose administered, Galecto has now begun a third phase II trial – specifically a 1b/2a trial. The substance is being tested as a treatment for liver cirrhosis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Galecto ditches high doses in phase II trial
For subscribers
